NEFH and neoplasm: In contrast, potentiated by the oncolytic activity of OAvs, the integration of OAv-NFH and VT-NF cells led to complete tumor regression in all of the treated mice (Fig. 6J–L) while maintaining a favorable safety profile (Appendix Fig. S10A,B), indicating the therapeutic benefits and the applicability of oncolytic viruses as a preferable transgenic vector for the integrative therapy in immunocompetent individuals.